Pancreatic Exocrine Cell Conversion via EZH2 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for Type 1 diabetes, such as whole pancreas or islet transplantation, face a shortage of organ donors and require immunosuppressive drugs, while using human embryonic stem cells for β-cell generation is hindered by practical and ethical barriers.
Innovation Solution
Inhibiting EZH2 in pancreatic exocrine cells using specific inhibitors to convert them into insulin-producing cells, characterized by increased expression of pancreatic and β-cell markers, capable of glucose-stimulated insulin secretion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If whole pancreas or islet transplantation is used to replace damaged β-cell mass, then clinical utility is proven, but shortage of organ donors and requirement of immunosuppressive drugs occur
Solution Approach 1:
The patent changes the cellular parameter by inhibiting EZH2 enzyme activity in pancreatic exocrine cells, which alters their differentiation potential. This enables mature exocrine cells to be converted into insulin-producing cells, creating a new cell source without requiring organ transplantation or stem cells, thus resolving the donor shortage issue while maintaining therapeutic efficacy
Solution Approach 2:
The patent creates functional copies of β-cells by converting exocrine cells through EZH2 inhibition. These copied cells replicate the insulin-producing function of native β-cells without requiring actual organ donation, effectively multiplying the available therapeutic cell supply from a single patient source
2Productivity
If human embryonic stem cells are used for β-cell generation, then infinite proliferation ability is achieved, but practical and ethical barriers exist
Solution Approach 1:
The patent uses readily available pancreatic exocrine cells from patient biopsies or surgical samples as the cell source. These cells can be easily obtained without ethical controversies, and while individual cells have limited lifespan, the process generates sufficient insulin-producing cells for therapy without requiring the infinite proliferation capability of stem cells
Solution Approach 2:
Instead of using embryonic stem cells and differentiating them into β-cells (the conventional approach), the patent inverts the approach by taking mature exocrine cells and converting them into insulin-producing cells through EZH2 inhibition. This reversal avoids stem cell ethics while achieving the desired therapeutic outcome
3Loss of time
If EZH2 inhibitor is applied to pancreatic exocrine cells, then rapid production of insulin-producing cells is achieved, but cell conversion process complexity increases
Solution Approach 1:
The patent achieves rapid cell conversion by targeting a specific molecular parameter (EZH2 enzyme activity) with a selective inhibitor. This single parameter change triggers a cascade of molecular events that quickly reprogram exocrine cells to express insulin and other β-cell markers, achieving conversion in days rather than months, thus reducing time loss despite the molecular complexity of the process
Data Source
AI summary
The present invention relates to methods and uses for producing an insulin-producing cell from a pancreatic exocrine cell comprising contacting the pancreatic exocrine cell with an inhibitor of EZH2. The present invention also relates to methods and uses for preventing or treating a disease involving dysfunctional insulin production.